Stockwatch: Premature evaluation
This article was originally published in Scrip
The way the stock price of a life science company moves in response to an event can reveal a lot more than whether 'the market' thinks the event is good or bad news. Last week, for instance, stock movements implied that Human Genome Science might not be sold for as little as $13 per share, and that Vertex would have to work very hard to warrant the surge in its valuation that followed its announcement of positive data in cystic fibrosis.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.